ArticleTranslational cancer research2025
Harnessing natural killer cell-related genes for prognostic and therapeutic advances in lung adenocarcinoma: a predictive model for survival and immunotherapy outcomes.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD), the most common subtype of non-small cell lung cancer (NSCLC), is characterized by high mortality rates and complex immune evasion mechanisms. Natural killer (NK) cells play a crucial role in tumor immune surveillance, with their activity regulated by specific genes. Recently, biomarkers derived from NK cell-related genes have garnered significant attention for their potential in predicting cancer prognosis. This study aimed to evaluate the clinical utility of a prognostic model based on NK cell-related genes in patients with LUAD. Methods: In this study, gene expression data and clinical information from LUAD patients were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and differentially expressed genes associated with natural killer cells (DENKCRGs) were identified. A prognostic risk score model was developed using least absolute shrinkage and selection operator (LASSO) regression and Cox regression analysis. The model's performance was subsequently validated through Kaplan-Meier survival curves, receiver operating characteristic (ROC) curves, enrichment analysis, and immune infiltration analysis. Additionally, its predictive capacity for immune therapy response and drug sensitivity was evaluated. Results: A total of 493 LUAD patient datasets were retrieved from TCGA, 857 from the GEO database, and 244 NK cell-related genes were identified based on prior studies. The filtered data were then partitioned into training and testing sets. Through LASSO regression and Cox regression analysis, eight genes ( Conclusions: The prognostic model developed in this study, based on NK cell-related genes, demonstrates considerable value in assessing the prognosis of LUAD. It not only serves as a predictor of patient survival but also provides a theoretical foundation for personalized immunotherapy and drug selection. Future research should focus on further validating the clinical applicability of this model and exploring its potential in the context of immunotherapy and targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.